Evolving survival gains in patients with young-onset colorectal cancer and synchronous resectable liver metastases

Eur J Surg Oncol. 2024 Apr;50(4):108057. doi: 10.1016/j.ejso.2024.108057. Epub 2024 Feb 23.

Abstract

We aimed to evaluate the practice and the associated outcomes of surgical treatment for young-onset colorectal cancer (YOCRC) patients presenting with synchronous liver metastases. The study cohort was divided into two groups according to surgery date: 131 patients in the early era (EE, 1998-2011) and 179 in the contemporary era (CE, 2012-2020). The CE had a higher rate of node-positive primary tumors, higher carcinoembryonic antigen level, and lower rate of RAS/BRAF mutations. The CE had higher rates of reverse or combined resection, multi-drug prehepatectomy chemotherapy, and two-stage hepatectomy. The median survival was 8.4 years in the CE and 4.3 years in the EE (p = 0.011). On multivariate analysis, hepatectomy in the CE was independently associated with improved overall survival (HR 0.48, p = 0.001). With a combination of perioperative systemic therapy, careful selection of treatment approach, and coordinated resections, durable cure can be achieved in YOCRC patients.

Keywords: Colorectal cancer; Liver metastasis; Liver resection; Survival; Young-onset colorectal cancer.

MeSH terms

  • Colorectal Neoplasms* / pathology
  • Hepatectomy / adverse effects
  • Humans
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / secondary
  • Liver Neoplasms* / surgery
  • Retrospective Studies